Evidence map›Paper›PMID 40347012›Full record

ArticleHLA2025

Human Cytomegalovirus Antigen Presentation by HLA-G in Infected Cells.

Mireia Altadill, Iñaki Álvarez, Michelle Ataya, Gemma Heredia, Elisenda Alari-Pahissa, Aura Muntasell, Manuel Llano, Jonas Fuchs, Carlos Vilches, Hartmut Hengel and 2 more

Abstract read
In one paragraph

Article in HLA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mireia AltadillDepartment of Medicine and Life Sciences, University Pompeu Fabra, Barcelona, Spain.
Iñaki ÁlvarezDepartment of Cell Biology, Physiology and Immunology, Institute of Biotechnology and Biomedicine, Autonomous University of Barcelona, Bellaterra, Spain.
Michelle AtayaDepartment of Medicine and Life Sciences, University Pompeu Fabra, Barcelona, Spain.
Gemma HerediaDepartment of Medicine and Life Sciences, University Pompeu Fabra, Barcelona, Spain.
Elisenda Alari-PahissaHospital del Mar Research Institute, Barcelona, Spain.
Aura MuntasellDepartment of Cell Biology, Physiology and Immunology, Institute of Biotechnology and Biomedicine, Autonomous University of Barcelona, Bellaterra, Spain.
Manuel LlanoBiological Sciences Department, The University of Texas at El Paso, El Paso, USA.
Jonas FuchsInstitute of Virology, Medical Center University of Freiburg, Freiburg, Germany.
Carlos VilchesImmunogenetics and Histocompatibility Lab, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain.
Hartmut HengelInstitute of Virology, Medical Center University of Freiburg, Freiburg, Germany.
Anne HaleniusInstitute of Virology, Medical Center University of Freiburg, Freiburg, Germany.
Miguel López-BotetDepartment of Medicine and Life Sciences, University Pompeu Fabra, Barcelona, Spain.ORCID 0000-0003-4882-065X

Funding

Agencia Estatal de Investigación PID2019-110609RB-C21-C22/AEI/10.13039/501100011033Deutsche Forschungsgemeinschaft FOR2830(HA6035/2-2;HE2526/9-2)
6 · The paper itself

Abstract

HLA-E and -G class Ib molecules were considered unrelated to viral antigen presentation. HLA-E binds nonamers from the leader sequences of other HLA-I molecules and the human cytomegalovirus (HCMV) UL40 protein, interacting with CD94/NKG2 NK cell receptors. Yet, evidence that HLA-E may present some pathogen-derived peptides to CD8+ T lymphocytes has been reported. By contrast, HLA-G binds a broad spectrum of endogenous sequences but its role in antigen presentation is unknown. An experimental approach was set up to search for HCMV antigens displayed by HLA-G in infected cells. Among the analysed peptidome, 22 sequences corresponding to 16 HCMV molecules were identified; 17 peptides were confirmed to interact in vitro with HLA-G of which 10 displayed characteristic anchor residues. As compared to the response in short-term (6 h) assays to immunodominant IE-1 and pp65 antigens, none of the HLA-G-binding peptides stimulated cytokine production by CD8+ T cells from HCMV-seropositive blood donors (n = 15). Following a 14-day peptide stimulation of PBMC and expansion with IL-2, CD8+ T cells specifically responding to a subset of these viral antigens were detected in some individuals, yet were not restricted by HLA-G in functional assays. A subset of viral peptides did bind to both HLA-G and -E but were not recognised by CD94/NKG2 NK cell receptors. Our results provide the first evidence that HLA-G may display potentially immunogenic viral peptides in HCMV-infected cells, yet do not support their ability to promote HLA-G-restricted CD8+ T cell responses nor to modulate NK cell functions.

Indexed as

Antigen PresentationAntigens, ViralCD8-Positive T-LymphocytesCytomegalovirusCytomegalovirus InfectionsHistocompatibility Antigens Class IHLA-G AntigensHLA-E AntigensHumansInterleukin-2NK Cell Lectin-Like Receptor Subfamily DPeptidesPhosphoproteinsProtein BindingViral Matrix ProteinsViral ProteinsAntigens, Viralcytomegalovirus matrix protein 65kDaHistocompatibility Antigens Class IHLA-E AntigensHLA-G AntigensInterleukin-2NK Cell Lectin-Like Receptor Subfamily DPeptidesPhosphoproteinsUL40 glycoprotein, CytomegalovirusViral Matrix ProteinsViral ProteinscytomegalovirusHLA‐EHLA‐GNK cellT lymphocyte

Identifiers

PMID40347012
PMCPMC12065092

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.